URGENT UPDATE: Nearly 581,000 bottles of a popular blood pressure medication have been recalled due to the presence of potentially cancer-causing chemicals, as confirmed by Teva Pharmaceuticals on October 7, 2023. This alarming recall has been classified as a Class II risk by the FDA on October 24, indicating that exposure may lead to temporary or medically reversible health consequences.
The recall affects three dosage strengths of prazosin hydrochloride capsules distributed nationwide. These capsules, primarily used to treat high blood pressure and prostate conditions, may also be prescribed off-label for post-traumatic stress disorder (PTSD) symptoms. The FDA has reported that the recalled capsules contain elevated levels of N-nitroso prazosin impurity, raising serious health concerns.
The specific recalled medications include:
– 1 mg capsules: 181,659 bottles (NDC 0093-4067-01 and 0093-4067-10), lot numbers 3010544A and 3010545A, expiring in October 2025.
– 2 mg capsules: 291,512 bottles (NDC 0093-4068-01 and 0093-4068-10), from multiple lot numbers, with expiration dates ranging from October 2025 through July 2026.
– 5 mg capsules: 107,673 bottles (NDC 0093-4069-01, 0093-4069-52, and 0093-4069-05), across various lot numbers, with expiration dates extending into 2026.
Patients currently taking the recalled medication are urged to consult their healthcare provider immediately. Stopping blood pressure medication suddenly can lead to serious health risks. Teva Pharmaceuticals has notified affected customers via letter, and the recall process is active.
For further information, patients with questions should reach out to their pharmacist or healthcare provider to determine if their medication is included in the recall and to discuss alternative treatment options.
This urgent recall underscores the critical importance of monitoring medication safety. As always, patients should stay informed and proactive about their health, especially in light of these troubling developments.
Stay tuned for updates as this story continues to unfold.
